GPC Laboratory Co. Ltd

Introduction of THP-G8 cell line for skin sensitisation test, IL-8 Luc assay, as a risk assessment of chemical substances (OECD TG. 442E)

KEY ACTIVITIES In vitro skin sensitisation test
SECTOR: Chemical risk assessment
KEY WORDS: OECD test guideline, Alternatives to animal testing
TYPE OF ACTIVITIES Services

Description:

IL-8 Luc assay is one of the in vitro skin sensitisation testing method in OECD test guideline 442E.

In contrast to assays analysing the expression of cell surface markers, IL8-Luc assay quantifies changes in IL-8 expression.

In the THP-1-derived IL-8 reporter cell line (THP-G8), IL-8 expression is measured following exposure to sensitisers.

The expression of luciferase is then used to aid discrimination between skin sensitisers and non-sensitisers.

 

Type of Partnership Sought:

1.License agreement
2.Commercial agency agreement

 

Additional information:

Hamamatsu Pharma Research specializes in pharmacological efficacy studies using nonhuman primate disease models in the following therapeutic areas: pain, osteoarthritis, cerebral ischemia/stroke, ophthalmology, endometriosis, and gastroenterology.

As nonhuman primates are phylogenetically and physiologically more similar to humans than rodents, the company’s NHP efficacy models will help customers to obtain preclinical POC relevant and translatable to clinical efficacy, which potentially adds value to their current preclinical discovery programs.

Products & Service Stage Outline
1) NHP models for stroke, pain, endometriosis, and osteoarthritis commercially available Pharmacological efficacy studycomprising four peptide antigens
2) NHP models for glaucoma, wet AMD and dry AMD. commercially available Pharmacological efficacy study
3) NHP models for IBD exploratory Pharmacological efficacy study

 

Company website